Global Triple-Negative Breast Cancer Treatment Market

Report ID : 1038 | Published : 2022-08-18 | Pages: 140 | Format: PDF/EXCEL

According to the latest research by InsightAce Analytic, the global Triple-Negative Breast Cancer Treatment market is valued at US$ 648.33 Million in 2021, and it is expected to grow with a CAGR of 4.37% during a forecast period of 2022-2030. Triple-Negative Breast Cancer is classified as a type of breast cancer wherein tumors lack progesterone receptor (PR), the estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2), and hence still there are no effective treatment methods for TNBC. TNBC is the leading cause of death in women.
There are multiple factors that drive the triple-negative breast cancer treatment market, such as the rising prevalence of triple-negative breast cancer, rising adoption of advanced medical technologies, medical errors reduction in cancer care, rising cost of cancer care, various government initiatives for the TNBC cancer therapy developments and increasing awareness among people about advance TNBC treatments. However, factors like the high cost of treatments, shortage of skilled medical oncologists, complex and time-consuming therapy procedures can limit the growth of the triple-negative breast cancer treatment market. Moreover, there is a short-term negative impact on TNBC market due to the COVID-19 pandemic. COVID-19 pandemic has raised many issues in the market, such as labor shortage and transportation restrictions.


The triple-negative breast cancer treatment market has been segmented into Drug Types, End-users, and Regions. The Drug Types segment comprises Doxorubicin, Cyclophosphamide, Paclitaxel, Docetaxel, Carboplatin/Cisplatin, and other Drug Type. Doxorubicin will be in high scope in the future as this chemotherapy drug is beneficial and effective in treating various types of cancers. Doxorubicin can also interact with cyclophosphamide and paclitaxel. By End-users, the market is divided into Hospitals, Cancer Research Institutes, and Retail Clinics. The Cancer Research Institutes segment will dominate the market because of the easy availability of facilities. At the regional level, the triple-negative breast cancer treatment market can be segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is expected to be the major market shareholder of this market, followed by Asia-Pacific, Europe, and Rest-of-the-World.
Major key Players of triple-negative breast cancer treatment market are AstraZeneca plc., Pfizer, Inc., F. Hoffman - La Roche Ltd., Channel Strategy, Novartis AG, Mylan N.V., Eli Lilly and Company, Celgene Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., and other Prominent Player.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Triple Negative Breast Cancer Treatment Market Snapshot

Chapter 4. Global Triple Negative Breast Cancer Treatment Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Competitive Landscape & Market Share Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Drug Types Estimates & Trend Analysis

5.1. By Drug Types & Market Share, 2019 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 for the following By Drug Types:

5.2.1. Doxorubicin

5.2.2. Cyclophosphamide

5.2.3. Paclitaxel

5.2.4. Docetaxel

5.2.5. Carboplatin/Cisplatin

5.2.6. Other Drug Type

Chapter 6. Market Segmentation 1: By End-Users Estimates & Trend Analysis

6.1. By End-Users & Market Share, 2019 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 for the following By End-Users:

6.2.1. Hospitals

6.2.2. Cancer Research Institutes

6.2.3. Retail Clinics

Chapter 7. Triple Negative Breast Cancer Treatment Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Triple Negative Breast Cancer Treatment Market revenue (US$ Million) estimates and forecasts By Drug Types, 2019 - 2030

7.1.2. North America Triple Negative Breast Cancer Treatment Market revenue (US$ Million) estimates and forecasts By End-Users, 2019 - 2030

7.1.3. North America Triple Negative Breast Cancer Treatment Market revenue (US$ Million) estimates and forecasts by country, 2019 - 2030

7.2. Europe

7.2.1. Europe Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By Drug Types, 2019 - 2030

7.2.2. Europe Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By End-Users, 2019 - 2030

7.2.3. Europe Triple Negative Breast Cancer Treatment Market revenue (US$ Million) by country, 2019 - 2030

7.3. Asia Pacific

7.3.1. Asia Pacific Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By Drug Types, 2019 - 2030

7.3.2. Asia Pacific Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By End-Users, 2019 - 2030

7.3.3. Asia Pacific Triple Negative Breast Cancer Treatment Market revenue (US$ Million) by country, 2019 - 2030

7.4. Latin America

7.4.1. Latin America Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By Drug Types, (US$ Million)

7.4.2. Latin America Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By End-Users, (US$ Million)

7.4.3. Latin America Triple Negative Breast Cancer Treatment Market revenue (US$ Million) by country, (US$ Million) 2019 - 2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By Drug Types, (US$ Million)

7.5.2. Middle East & Africa Triple Negative Breast Cancer Treatment Market revenue (US$ Million) By End-Users, (US$ Million)

7.5.3. Middle East & Africa Triple Negative Breast Cancer Treatment Market revenue (US$ Million) by country, (US$ Million) 2019 - 2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. AstraZeneca plc.

8.2.2. Pfizer, Inc.

8.2.3. F. Hoffman - La Roche Ltd.

8.2.4. Channel Strategy

8.2.5. Novartis AG

8.2.6. Mylan N.V.

8.2.7. Eli Lilly and Company

8.2.8. Celgene Corporation

8.2.9. Sanofi S.A.

8.2.10. Johnson & Johnson Services, Inc.

8.2.11. Other Prominent Player

Global Triple-Negative Breast Cancer Treatment Market Segmentation

Global Triple-Negative Breast Cancer Treatment Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 Based on Drug Types

  • Doxorubicin
  • Cyclophosphamide
  • Paclitaxel
  • Docetaxel
  • Carboplatin/Cisplatin
  • Other Drug Type

Global Triple-Negative Breast Cancer Treatment Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 Based on End-Users

  • Hospitals
  • Cancer Research Institutes
  • Retail Clinics

Global Triple-Negative Breast Cancer Treatment Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 Based on Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Triple-Negative Breast Cancer Treatment Market Revenue (US$ Million) By Country, 2019 To 2030

  • U.S.
  • Canada

Europe Triple-Negative Breast Cancer Treatment Market Revenue (US$ Million) By Country, 2019 To 2030

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Triple-Negative Breast Cancer Treatment Market Revenue (US$ Million) By Country, 2019 To 2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Triple-Negative Breast Cancer Treatment Market Revenue (US$ Million) By Country, 2019 To 2030

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Triple-Negative Breast Cancer Treatment Market Revenue (US$ Million) By Country, 2019 To 2030

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$10000
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..